Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia (PITVIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01861535

Recruitment Status : Completed

First Posted : May 23, 2013

Last Update Posted : April 14, 2021

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Austrian Science Fund (FWF)

Information provided by (Responsible Party):

Medical University of Graz

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	February 2021
Actual Study Completion Date :	February 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Trutnovsky G, Reich O, Joura EA, Holter M, Ciresa-Konig A, Widschwendter A, Schauer C, Bogner G, Jan Z, Boandl A, Kalteis MS, Regauer S, Tamussino K. Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial. Lancet. 2022 May 7;399(10337):1790-1798. doi: 10.1016/S0140-6736(22)00469-X. Epub 2022 Apr 25. Erratum In: Lancet. 2022 Oct 8;400(10359):1194.

To Top